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Increased healthcare expenditures are not a guarantee 
for better overall health of a population. Diabetes, 
especially type 2, is responsible for substantial healthcare 
expenditures in the US, the Netherlands and many other 
countries in Europe, but despite increasing economic costs 
the prevalence of diabetes and its complications continues 
to rise.1,2 Overall the US spends per capita on healthcare 
almost double the average of other Organisation Economic 
Co-operation and Development (OECD) countries.1,3 
Nevertheless, despite these higher economic costs, the 
Americans are not gaining benefits that commensurate 
with these higher expenditures: dozens of countries today 
even boast superior life expectancy compared with the US,3 
showing that the healthcare expenditures as such do not go 
hand in hand with better health. 
In this issue of the Netherlands Journal of Medicine, 
Peters et al. present a literature review which aimed to 
determine the current total economic burden of diabetes 
and its complications in the Netherlands.4 They found 
that the total costs of diabetes were quite similar to 
those previously reported in the UK by Hex et al.5 Peters 
et al. further came to the conclusion that diabetes and 
especially its complications pose a substantial burden 
on the Netherlands and predicted that this burden will 
increase further in the near future due to changing 
demographics and lifestyle. They suggested that a further 
rise in costs is unavoidable and cannot be halted in the 
near future. 
One of the major limitations of descriptive cost analyses, 
such as those conducted by Peters et al., is that they do 
not provide an indication of the value obtained for the 
money spent. The chronic nature of diabetes and the high 
incidence of complications are the main reasons behind 
the high costs involved.1 Complications related to diabetes 
account for a substantial proportion of the direct health 
costs.5 Therefore, with increasing prevalence of diabetes 
the costs of treating complications will grow if current 
care regimes and strategies are maintained without any 
changes.5 
Because the risk of developing diabetes and its 
complications further increases with age, the ageing 
population is expected to drive a substantial increase in 
the incidence of diabetes even if other risk factors remain 
unchanged.1 As the total costs are proportional to the size 
of the affected population, stemming the rise in costs 
for diabetes will only be possible by successful diabetes 
prevention.6 Thus primary prevention may provide the 
greatest potential to reduce costs. 
In this respect type 2 diabetes can function as a good 
model for management of other chronic diseases.7 
Modern obesogenic environments, with the combination 
of unhealthy diet and physical inactivity, have serious 
implications for type 2 diabetes, and many other 
chronic diseases. However, it has been shown that type 
2 diabetes and its complications, especially for people at 
high risk, can be delayed or even avoided by prevention 
programs.8-10 Evidence from large trials in Finland as well 
as real-world prevention programs have identified that 
lifestyle interventions can prevent or delay the onset of 
type 2 diabetes in people at high risk.8-10 Specifically the 
risk of developing type 2 diabetes can be reduced over a 
3-5 year period for people with impaired fasting glucose 
tolerance by intensive lifestyle modification programs 
(58%) and pharmacological interventions (31%).10 
Ideally, prevention programs should combine broad 
population-based primary prevention strategies for other 
chronic diseases, such as cardiovascular disease and 
cancer, while simultaneously targeting people at high risk 
of developing diabetes.11,12 In addition, research has also 
shown the benefits of an integrated approach in the case of 
subjects who have developed type 2 diabetes: intensifying 
treatment including tight control of multiple risk factors 
as high blood glucose, blood pressure and cholesterol have 
been found to significantly reduce the risk of death from 
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cardiovascular diseases and the development of end-stage 
renal disease.7,8
Health promotion and the prevention of chronic diseases 
often has a low priority and as a consequence receives 
too small a share of the overall healthcare budget. The 
focus is often mainly on care for people who have already 
developed a disease.7,11 In their paper Peters et al. also do 
not present data about the costs of prevention of diabetes 
in the Netherlands.4 
It is time for a treatment paradigm shift in light of 
the proven, evidence-based, value of early intensive 
treatment in preventing diabetes and its chronic diabetes 
complications.13 What is needed is the introduction of a 
comprehensive and integrated patient-centred approach 
that focuses on health promotion and starting early 
interventions to prevent the development of diabetes 
and its complications.7,13 Such an approach is relatively 
inexpensive to implement and highly cost-effective 
compared with the actual costs of treating the 
complications of diabetes. 
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